Monday, 12 May 2014

Lilly's Basal Insulin Peglispro Shows Superiority in HbA1c Reduction Compared to Insulin Glargine in Three Phase III Trials in Patients with Type 2 Diabetes

Eli Lilly today announced positive top-line results of three completed Phase III clinical trials in patients with type 2 diabetes for basal insulin peglispro (BIL), which is being studied as a once-daily treatment for both type 1 and type 2 diabetes (Lilly)


Launch of a new alliance for the global assessment of retinopathy

A new project has been launched to assess the awareness, treatment and implications of diabetic retinopathy globally. Results are intended to inform decision-making and policy development around this common and serious complication of diabetes (International Diabetes Federation )


Efficacy of REAL-Time continuous glucose monitoring on glycaemic control and glucose variability in Type 1 diabetic patients treated with either insulin pumps or multiple insulin injection therapy

Appropriate use of REAL-Time CGM improved glyco-metabolic control in T1D patients. The effects of CGM were more evident in patients under MDI treatment, compared to CSII. Glucose variability, in addition to glycaemic control, was improved in compliant diabetic patients. This article is protected by copyright (Diabetes/Metabolism Research and Reviews)


Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial

IDegAsp BID effectively improves HbA1c and fasting PG levels with fewer hypoglycemia episodes versus BIAsp 30 in patients with uncontrolled type 2 diabetes previously treated with once- or twice-daily pre- or self-mixed insulin (Diabetes Care)


ß-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment

This article examines the foundation of ß-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment (Diabetes Care)


Role of epigenetic mechanisms in the development of chronic complications of diabetes

Our review suggests that the treatment of chronic complications should focus on erasing metabolic memory by targeting chromatin modification enzymes and by restoring miRNA levels (Diabetes Research and Clinical Practice)


Ten years of the national genetic diabetes nurse network: a model for the translation of genetic information into clinical care

The GDN project has proved an effective, innovative means of disseminating new genetic information from a centre of excellence and is suggested as a model for the successful and rapid dissemination of genetic information into routine clinical care in other conditions (Royal College of Physicians)

No comments:

Post a Comment